Literature DB >> 26287888

Mydriatic insert and intracameral injections compared with mydriatic eyedrops in cataract surgery: controlled studies.

Anders Behndig1, Jean-François Korobelnik2.   

Abstract

UNLABELLED: Mydriatic eyedrops are the standard method for pupil dilation in cataract surgery, but their limitations have prompted a search for alternative techniques. Two alternatives-an ophthalmic insert containing phenylephrine and tropicamide and intracameral injections of various combinations of lidocaine, cyclopentolate, and phenylephrine, with or without epinephrine in the irrigating solution-have been assessed in prospective controlled studies, including randomized controlled trials (RCTs). We reviewed the safety and efficacy of mydriatic ophthalmic inserts and intracameral mydriatic injections compared with the safety and efficacy of mydriatic eyedrops using a systematic PubMed search (1963 to 2014). We identified 9 prospective studies (7 RCTs, 637 patients) of the mydriatic ophthalmic insert and 15 prospective studies (14 RCTs, 1020 patients) of intracameral mydriatic injections; 7 of the RCTs compared intracameral mydriatic injections and mydriatic eyedrops and 7 RCTs studied the optimum intracameral mydriatic injection protocol. The latter showed that a lidocaine and phenylephrine-based solution, without irrigating epinephrine, was optimum for intracameral mydriatic injections. The mydriatic ophthalmic insert and intracameral mydriatic injections were consistently shown to be safe and as effective as mydriatic eyedrops. Each method has distinct advantages and limitations. FINANCIAL DISCLOSURE: Dr. Behndig has received fees from Théa Pharma GmbH as a member of the European Team for the Prophylaxis of Infection in Cataract Surgery group. Dr. Korobelnik has received consultancy fees from Alcon Surgical, Inc.; Allergan, Inc.; Alimera, Inc.; Bayer HealthCare AG; Carl Zeiss Meditec AG; Novartis Corp.; Roche Innovatis AG; and Théa Pharma GmbH.
Copyright © 2015 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26287888     DOI: 10.1016/j.jcrs.2014.12.050

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  5 in total

1.  Assessing the accuracy of intracameral phenylephrine preparation in cataract surgery.

Authors:  Stuart Guthrie; Thomas Jensen; Richard C Hartley; Kanna Ramaesh; David Lockington
Journal:  Eye (Lond)       Date:  2018-06-15       Impact factor: 3.775

2.  Design and fabrication of drug-eluting polymeric thin films for applications in ophthalmology.

Authors:  Lampros Lamprogiannis; Athanasios Karamitsos; Varvara Karagkiozaki; Ioannis Tsinopoulos; Maria Gioti; Dimitrios G Fatouros; Stavros Dimitrakos; Stergios Logothetidis
Journal:  IET Nanobiotechnol       Date:  2018-12       Impact factor: 1.847

3.  In Situ Gelling Ophthalmic Drug Delivery System for the Optimization of Diagnostic and Preoperative Mydriasis: In Vitro Drug Release, Cytotoxicity and Mydriasis Pharmacodynamics.

Authors:  Pierre-Louis Destruel; Ni Zeng; Françoise Brignole-Baudouin; Sophie Douat; Johanne Seguin; Elodie Olivier; Melody Dutot; Patrice Rat; Sophie Dufaÿ; Amélie Dufaÿ-Wojcicki; Marc Maury; Nathalie Mignet; Vincent Boudy
Journal:  Pharmaceutics       Date:  2020-04-15       Impact factor: 6.321

4.  Antiseptic effect of low-concentration povidone-iodine applied with a depot device in the conjunctiva before cataract surgery.

Authors:  Simon Wass; Grethe Albrektsen; Maria Tjåland Ødegård; Mari Sand; Dordi Austeng
Journal:  Eye (Lond)       Date:  2018-08-31       Impact factor: 3.775

5.  Pharmacologic interventions for mydriasis in cataract surgery.

Authors:  Mustafa Iftikhar; Samuel A Abariga; Barbara S Hawkins; Sidra Zafar; Tahreem A Mir; Henry Jampel; Fasika A Woreta
Journal:  Cochrane Database Syst Rev       Date:  2021-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.